<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="project_funders\PMC6553876\results\search\funders\results.xml">
  <result pre="– original draftWriting – review &amp;amp; editing1*[1], Texas Therapeutics Institute," exact="Brown Foundation" post="Institute of Molecular Medicine, University of Texas Health Science"/>
  <result pre="States of America[2], Department of Infectious Diseases and Vaccines Research," exact="Merck" post="Research Laboratories, Merck and Co. Inc., Kenilworth, New Jersey,"/>
  <result pre="Department of Infectious Diseases and Vaccines Research, Merck Research Laboratories," exact="Merck" post="and Co. Inc., Kenilworth, New Jersey, United States of"/>
  <result pre="Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology," exact="Chinese Academy of Sciences," post="Beijing, ChinaKuhnRichard J.Editor[], Purdue University, UNITED STATES I have"/>
  <result pre="Institute of Microbiology, Chinese Academy of Sciences, Beijing, ChinaKuhnRichard J.Editor[]," exact="Purdue University," post="UNITED STATES I have read the journal’s policy and"/>
  <result pre="following competing interests: Some of the coauthors are employees of" exact="Merck" post="Co. Inc.; JMP, TB, and BJD are employees of"/>
  <result pre="Integral Molecular. ¤aCurrent address: Gehr Leukemia Center, City of Hope" exact="National Medical Center," post="Duarte, California, United States of America ¤bCurrent address: Sanofi"/>
  <result pre="Medical Center, Duarte, California, United States of America ¤bCurrent address:" exact="Sanofi" post="Pasteur, Swiftwater, Pennsylvania, United States of America * E-mail:"/>
  <result pre="Health HHSN272201400058CDoranzBenjamin J. This study was funded by grants from" exact="Merck" post="&amp;amp; Co., Inc. (Kenilworth, NJ), the Texas Emerging Technology"/>
  <result pre="by grants from Merck &amp;amp; Co., Inc. (Kenilworth, NJ), the" exact="Texas Emerging Technology Fund," post="and the Welch Foundation (Grant No. AU-0042-20030616). This study"/>
  <result pre="Inc. (Kenilworth, NJ), the Texas Emerging Technology Fund, and the" exact="Welch Foundation" post="(Grant No. AU-0042-20030616). This study was also supported by"/>
  <result pre="rDEN3-rDEN3Δ30/31-7164; and rDEN4-rDEN4 Δ30–7132,7163,8308). The tetravalent dengue subunit vaccine (V180," exact="Merck" post="and Co. Inc.) comprises truncated forms of envelope proteins"/>
  <result pre="raised and maintained at New Iberia Research Center (NIRC) of" exact="University of Louisiana at Lafayette," post="New Iberia, LA, USA. Flavivirus naïve (i.e. sera negative"/>
  <result pre="in this study. The animal studies were approved by the" exact="University of Louisiana at Lafayette" post="Institutional Animal Care and Use Committee (IACUC) and conducted"/>
  <result pre="Virus Vaccine Compositions And Methods of Use Thereof. United States:" exact="Merck" post="Sharp &amp;amp; Dohme Corp. (Rahway, NJ, US). 22MengW, LiL,"/>
  <result pre="the preferential recognition of immature flaviviruses by a fusion-loop antibody." exact="EMBO" post="J28: 3269–3276. 10.1038/emboj.2009.24519713934 48DaiL, SongJ, LuX, DengYQ, MusyokiAM, et"/>
  <result pre="conformation of E protein monomers assembled on the virus surface." exact="EMBO" post="Mol Med6: 358–371. 10.1002/emmm.20130340424421336 50CockburnJJ, Navarro SanchezME, GoncalvezAP, ZaitsevaE,"/>
  <result pre="neutralization mechanism of a higher primate antibody against dengue virus." exact="EMBO" post="J31: 767–779. 10.1038/emboj.2011.43922139356 51DejnirattisaiW, WongwiwatW, SupasaS, ZhangX, DaiX, et"/>
 </snippets>
</snippetsTree>
